Breztri™ Aerosphere® now available in Canada for long-term maintenance treatment of COPD

/CNW/ - Today, AstraZeneca announced the Canadian availability of Breztri™ Aerosphere® (budesonide/glycopyrronium/formoterol fumarate dihydrate), indicated for...

Related Keywords

Canada ,China ,Japan ,Ottawa ,Ontario ,Canadians ,Canadian ,Mary Anne Cedrone ,Alex Romanovschi ,Jean Bourbeau ,Peter Glazier ,Lung Health Foundation ,Astrazeneca Canada Inc ,Global Initiative For Chronic Obstructive Lung Disease ,World Health Organization ,Epidemiology Biostatistics At Mcgill University ,Canadian Institute For Health Information ,Astrazeneca ,Canadian Lung Association ,Scientific Affairs ,Research Seminar Faculty ,Health Canada ,Breztri Aerosphere ,Executive Vice President ,Lung Health ,Vice President ,New England Journal ,Medicinein June ,Lancet Respiratory Medicinein September ,Trixeo Aerosphere ,Rare Disease ,Canadian Product ,Global Initiative ,Chronic Obstructive Lung Disease ,Eur Respir ,Allergy Asthma ,Health Foundation ,Accessed September ,Chronic Obstructive Lung ,Inpatient Hospitalization ,Newborn Statistics ,Canadian Lung ,Triple Therapy ,Two Glucocorticoid Doses ,Very Severe ,Englj Med ,Eur Resp ,General Practice Based Population ,Chronic Obstructive Pulmonary ,Resp Crit Care ,One Year Mortality ,Their Predictors ,Patients Hospitalized ,Nationwide Population Based ,Zeneca Canada ,Astrazeneca Canada ,